| Literature DB >> 24900545 |
Nancy-Ellen Haynes1, Nathan R Scott1, Li C Chen1, Cheryl A Janson1, Jia Kui Li1, Christine M Lukacs1, Aruna Railkar1, Effie Tozzo1, Toni Whittard1, Nicholas F Brown1, Adrian Wai-Hing Cheung1.
Abstract
3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl]-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.Entities:
Keywords: JNK selective inhibitor; adamantyl azaquinolone; kidney disease
Year: 2012 PMID: 24900545 PMCID: PMC4025727 DOI: 10.1021/ml300175c
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345